- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02251210
Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis
Three Month, Randomised, Double-blind, Double-dummy, Placebo-controlled, Multiple Dose-range Study of the Efficacy and Safety of BIIL 284 BS (5, 25 and 75 mg p.o. Once Daily) in Adult Patients With Active Rheumatoid Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients of >=18 and <= 70 years of age
Patients suffering from rheumatoid arthritis as defined by the American Rheumatism Association (ARA) criteria revised 1987 and date of diagnosis >= 6 months. At least 4 of the following 7 criteria must be present:
- Morning stiffness in and around the joints lasting at least 1 hour before maximal improvement for at least 6 weeks
- Arthritis (soft tissue thickening or fluid - not bony overgrowth alone) of at least 3 joint areas for at least 6 weeks
- Arthritis of hand joints (at least one area swollen in a wrist, metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joint) for at least 6 weeks
- Symmetrical arthritis (observed by a physician) with simultaneous involvement of the joints on both sides of the body for at least 6 weeks
- Rheumatoid nodules (observed by a physician) over bony prominence or extensor surfaces or in juxta-articular regions
- Serum rheumatoid factor positive
- X-ray changes typical of rheumatoid arthritis (erosions or unequivocal bony decalcification localized in or most marked adjacent to the involved joints)
- Patients belonging to the RA functional class I, II or III
Active RA as defined at visit 2 by:
- Swollen joint count at least of 6 (of 28 joints examined) and
- Tender joint count at least of 8 (of 28 joints examined) and
Patients must fulfil 2 out of the 3 following criteria:
- Patient's assessment of pain (VAS) >= 40 mm
- Investigator's global assessment of disease activity on a VAS >= 40 mm
- ESR >= 28 mm/h or CRP >= 20 mg/L
- Patient's written informed consent obtained at Visit 1 (screening) before enrolment in the study
Exclusion Criteria:
- Patient presenting or having a history of inflammatory rheumatic disease other than RA (e.g.: mixed connective tissue disease, systemic lupus erythematosus, seronegative spondyloarthropathy)
- Patients who have failed to more than 3 different disease-modifying antirheumatic drug (DMARDs) therapies previously due to lack of efficacy (in case of combined therapy each DMARDs used is counted as one)
- Patients with any other disease that could interfere with the evaluation of efficacy and safety
Patients in treatment with any DMARDs / slow-acting anti-rheumatic drug (SAARDs) during the periods specified:
- 4 weeks before V2: Methotrexate, parenteral/oral gold, D-penicillamine, Sulphasalazine, antimalarials (e.g.:Chloroquine/Hydroxychloroquine), Azathioprine, Cyclosporine A, Alkylating agents (e.g.: Cyclophosphamide / Chlorambucil), Minocycline, Etanercept (Enbrel®), and Leflunomide (only if wash-out with Colestyramine has been done after leflunomide discontinuation)
- 3 months before Visit 2: Leflunomide if no wash- out with colestyramine has been done after leflunomide discontinuation, Infliximab (Remicade®), any other biological compound.
- Patient in treatment with oral corticosteroids at a dose higher than 10 mg/day or 0.2 mg/Kg/day (prednisone equivalent) whichever is lower, during the 4 weeks prior to Visit 2, change in the treatment with oral corticosteroids during the 4 weeks prior to Visit 2 or intended change during the trial
- Patients in treatment with any parenteral (intravenous, intramuscular or intraarticular) treatment with corticosteroids during the 4 weeks prior to Visit 2 or their intended use during the trial.
- Change in treatment with non-steroidal anti-inflammatory drugs (NSAIDs) during the 2 weeks prior to Visit 2 or any intended change during the trial.
- Synovectomy, and/or surgical treatment for RA in the previous 3 months prior to visit 2 or intended indication during the trial.
- Synoviorthesis in the previous 4 weeks prior to Visit 2 or intended indication during the trial.
- Patients in treatment with any other leukotriene inhibitors such as montelukast or zafirlukast 4 weeks prior to Visit 2 or intended use during the trial.
- Initiation of physiotherapy during the 2 weeks before V2, or intended change during the trial
- Patients with history of cardiovascular, renal, neurologic, psychiatric, liver, gastrointestinal (including lactose intolerance ), immunologic or endocrine dysfunction if they are clinically significant.
- Patients with any other known condition or circumstance, which would in the investigator's opinion, prevents compliance or completion of the study
- Patients with history of cancer within the past 5 years, excluding treated basal cell carcinoma
- Patients with chronic infection or acute infections during the 4 weeks before visit 1
- Patients with known positive serology for hepatitis B or C
- Patients with anticoagulant treatment (i.e. dicumarol or derivatives, warfarin)
Any of the following abnormal laboratory parameters at Visit 2:
- Impaired hepatic function, defined by serum levels of either Aspartate Aminotransferase (AST)(SGOT), Alanine Aminotransferase (ALT) (SGPT), alkaline phosphatase or bilirubin > 2 x upper limit of normal (ULN)
- Impaired renal function, defined by serum creatinine > 133 mmol/L (1.5 mg/dl)
- Hemoglobin values < 10 g/dl
- White blood cell count <= 3.500 cells/mm3
- Platelet count of less than 120.000/mm3
- Severe hypoproteinemia (e.g. in case of severe liver disease or nephrotic syndrome) with albumin < 3.0 g/dl
- Patients with any other abnormal, clinically relevant laboratory values not related to RA
- Patients participating in another clinical trial during the 3 months prior to visit 2
- Previous participation in the randomised period of this study
- Patients with a significant history and/or active alcohol or drug abuse Significant is defined as that which in the opinion of the investigator may either put the patient at risk because of participation in the study or may influence the results of the study or the patient's ability to participate in the study
- Pregnancy (to be excluded by pregnancy test at visit 1) or breast feeding, and sexually active women with childbearing potential not using a medically approved method of contraception (i.e. oral contraceptives, intrauterine devices, or double-barrier) for at least one month before and throughout the study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: BIIL 284 BS low dose
|
|
Experimental: BIIL 284 BS medium dose
|
|
Experimental: BIIL 284 BS high dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of patients achieving 20% improvement assessed by the American College of Rheumatology (ACR) criteria (ACR20)
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with adverse events
Time Frame: up to 3 months
|
up to 3 months
|
|
Percentage of patients achieving 50% improvement (ACR50)
Time Frame: 3 months
|
3 months
|
|
Number of withdrawals due to lack of efficacy
Time Frame: up to 3 months
|
up to 3 months
|
|
Number of swollen joints
Time Frame: up to 3 months
|
up to 3 months
|
|
Number of tender joints
Time Frame: up to 3 months
|
up to 3 months
|
|
Patient's assessment of pain on a visual analog scale (VAS)
Time Frame: up to 3 months
|
up to 3 months
|
|
Patient's global assessment of disease activity by VAS
Time Frame: up to 3 months
|
up to 3 months
|
|
Investigator's global assessment of disease activity by VAS
Time Frame: up to 3 months
|
up to 3 months
|
|
Patient's assessment of physical function
Time Frame: up to 3 months
|
via Health Assessment Questionnaire (HAQ)
|
up to 3 months
|
Change in erythrocyte sedimentation rate (ESR)
Time Frame: up to 3 months
|
up to 3 months
|
|
Change in C-reactive protein (CRP)
Time Frame: up to 3 months
|
up to 3 months
|
|
Change in Quality of Life
Time Frame: baseline, 3 months
|
assessed by the SF-36 questionnaire
|
baseline, 3 months
|
Change in Disease Activity Score (DAS 28)
Time Frame: baseline, up to 3 months
|
Disease Activity Score in 28-joint count
|
baseline, up to 3 months
|
Change in duration of morning stiffness
Time Frame: up to 3 months
|
up to 3 months
|
|
Consumption of rescue medication
Time Frame: up to 3 months
|
up to 3 months
|
|
Number of withdrawals due to adverse events
Time Frame: up to 3 months
|
up to 3 months
|
|
Final global assessment of tolerability by investigator on a 4-point scale
Time Frame: 3 months
|
3 months
|
|
Patient's assessment of fatigue by VAS
Time Frame: up to 3 months
|
up to 3 months
|
|
Number of patients with clinically significant changes in laboratory findings
Time Frame: up to 3 months
|
up to 3 months
|
|
Number of patients with clinically significant changes in vital signs
Time Frame: up to 3 months
|
up to 3 months
|
|
Number of patients with clinically significant changes in 12-lead ECG
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 543.27
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Rheumatoid
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
David Grant U.S. Air Force Medical CenterCompleted
-
TcLand Expression S.A.European CommissionTerminatedRheumatoId ArthritisFrance, Netherlands, Turkey, Czechia, Israel
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States